The rate of growth of health spending remains moderate. One area where prices appear to be increasing faster than they have in the past few years is brand-name prescription drugs. Specialized drugs for smaller patient populations have been launched with high nominal prices. Reducing prices of specialty drugs requires improving the productivity of R&D.